Healthcare Scan

Scan

Healthcare Scan

Scan symbols 19
SYKISRGMDTDXCMABTPFEMRKLLYGILDAMGNBIIBJNJUNHCVSVEEVTMOVRTXMRNAZTS
Watchlists 1
@healthcare
raw scan snapshot — prices as of scan date, not live 40 rows · screens, not recommendations

Healthcare is the week's sector-of-the-week — MRK +10.2% 7D (near ATH), JNJ +6.6% 7D (near ATH, RSI 72), LLY +2.7% 7D (+37.8% 3M), UNH at ATH; large-cap pharma and managed care both extended now; the only clean non-ATH setups are AMGN (basing, +8.7% vs SMA200) and PFE (RSI 36, lone deep-oversold).

Source: healthcare.json. Latest bar 2026-06-26 (VRTX stale 2026-06-25).

Quick Snapshot

Signal Reading
Overall 🟠 XLV week's sector leader — large-cap pharma (JNJ/MRK/LLY) + managed care (UNH/CVS) all at or near ATH with RSI 71-73; MRNA +82% vs VWAP (parabolic); bifurcation narrowed to only ISRG/ZTS still collapsing
Leaders MRK (RSI 70.8, +10.2% 7D, near ATH, +22.7% vs SMA200); JNJ (RSI 72.4, +6.6% 7D, near ATH, +18.3% vs SMA200); UNH (RSI 72.6, +66.1% 3M, at ATH, +29% vs SMA200); LLY (RSI 72.7, +37.8% 3M, near ATH)
Laggards PFE (RSI 36.2↓, -5.2% 7D, -7.3% 30D, below SMA20/50/200); ZTS (RSI 36.6, -32.6% 3M, collapse, -35.6% vs SMA200); ISRG (RSI 41.6, -10.6% 3M, collapse DC)
Froth flags MRNA +82% vs VWAP (poc $25.22 — truly parabolic); UNH +37.2% vs VWAP; CVS +35.1% vs VWAP; JNJ +24.3% vs VWAP — managed care / large-cap pharma is fully priced near-term
Key insight The managed care + pharma re-rate is confirmed but near exhaustion; the new EOW rotation entry is AMGN (basing, reasonable VWAP) and PFE (lone oversold contrarian watch, RSI 36 on the SMA200)

Price Table

Stock Price RSI vs SMA20 7D% 30D% 3M% 52wkHi% Trend Signal
PFE $24.29 36.2 ↓ -4.5% -5.2% -7.3% -8.7% -15.5% down GC 🔍 Watch (oversold, GC, -3.8% vs SMA200)
ZTS $76.09 36.6 ↓ -3.2% +1.4% -4.3% -32.6% -53.0% strong-down DC ❌ Broken
ISRG $404.70 41.6 ↓ -1.6% -0.3% -3.3% -10.6% -33.0% strong-down DC ❌ Broken
DXCM $70.14 48.9 ↓ -3.8% -1.8% -0.2% +12.7% -22.1% up DC 🔍 Watch
GILD $127.88 51.7 +1.3% -0.1% -3.7% -4.1% -18.7% down GC 🔍 Watch
VEEV $171.36 57.0 +2.8% +3.4% +8.1% -0.7% -44.8% weak-up DC ⚠️ Avoid (-20.4% vs SMA200, -18.4% vs VWAP)
MDT $80.98 55.2 +2.0% +2.5% +6.6% -7.1% -23.8% weak-up DC 🔍 Watch
AMGN $358.33 62.3 +3.9% +3.2% +6.6% +3.5% -8.4% strong-up GC 📈 Accumulate
ABT $94.12 63.3 +5.1% +6.7% +9.9% -8.9% -31.5% weak-up DC 🔍 Watch (-15.7% vs SMA200)
SYK $332.71 65.2 +8.3% +4.0% +8.8% +1.9% -17.8% weak-up DC 🔍 Watch (-4.3% vs SMA200)
TMO $513.03 66.5 +6.9% +10.1% +12.6% +8.5% -20.3% weak-up DC 🔒 Hold (-2.3% vs SMA200, approaching reclaim)
VRTX‡ $480.18 69.2 +6.8% +4.8% +10.2% +5.8% -5.5% up DC 🔒 Hold
BIIB $216.03 69.3 +9.3% +2.8% +9.7% +17.5% -0.9% strong-up GC 🔒 Hold (+30.3% vs VWAP — getting extended)
MRNA $67.27 71.4 ↑ +25.9% +1.8% +41.3% +35.7% -2.9% strong-up GC ⚠️ PARABOLIC (+82% vs VWAP, poc $25.22)
MRK $128.66 70.8 ↑ +8.9% +10.2% +7.8% +8.3% -0.1% strong-up GC ⚠️ Extended (near ATH, +30.5% vs VWAP)
CVS $104.34 71.8 ↑ +6.4% +3.4% +13.3% +50.2% -1.7% strong-up GC ⚠️ Extended (near ATH, +35.1% vs VWAP)
UNH $427.89 72.6 ↑ +6.8% +2.8% +12.1% +66.1% +0.02% strong-up GC ⚠️ Extended (at ATH, +37.2% vs VWAP)
JNJ $254.66 72.4 ↑ +8.7% +6.6% +10.1% +6.5% -0.2% strong-up GC ⚠️ Extended (near ATH, +24.3% vs VWAP)
LLY $1,208.12 72.7 ↑ +7.7% +2.7% +11.6% +37.8% -0.6% strong-up GC ⚠️ Extended (near ATH, +33.6% vs VWAP)

‡VRTX stale (2026-06-25 bar).

Tier Analysis

Collapsed / Broken (RSI < 43)

  • PFE ($24.29, RSI 36) — Pfizer: down, GC intact, -3.8% vs SMA200, -5.2% 7D. RSI 36 = deepest oversold in the scan. GC is technically in place but all three SMAs are overhead. Lone contrarian watch — probe only on a confirmed turn off the lows; do not catch mid-flush.
  • ZTS ($76.09, RSI 37) — Zoetis: collapse, DC, -35.6% vs SMA200, -32.6% 3M, -53% from ATH. Worst performer in the scan for the third consecutive week. No sign of reversal. Avoid.
  • ISRG ($404.70, RSI 42) — Intuitive Surgical: collapse, DC, -17.3% vs SMA200, -10.6% 3M, -33% from ATH. Device competition (J&J Ottava, MDT Hugo) continues to compress multiple. Avoid.

Neutral / Watch (RSI 49–66)

  • GILD ($127.88, RSI 52) — Gilead: down, GC, -0.2% vs SMA200. Basing on the SMA200; flat 30D. Watch — cleanest oversold-adjacent setup outside of PFE.
  • DXCM ($70.14, RSI 49) — Dexcom: up, DC, +4.3% vs SMA200, -1.8% 7D. Flat 30D in a mixed trend; not broken, not a buy.
  • MDT ($80.98, RSI 55) — Medtronic: weak-up, DC, -10.8% vs SMA200. +6.6% 30D relief bounce still below the 200. Device downtrend not finished.
  • VEEV ($171.36, RSI 57) — Veeva: weak-up, DC, -20.4% vs SMA200, -44.8% from ATH, -18.4% vs VWAP. Healthcare-SaaS multiple compression ongoing; avoid.
  • ABT ($94.12, RSI 63) — Abbott: weak-up, DC, -15.7% vs SMA200, +6.7% 7D bounce. Same relief-rally-in-downtrend pattern as TMO but further from the 200.
  • SYK ($332.71, RSI 65) — Stryker: weak-up, DC, -4.3% vs SMA200, bounced +4% 7D. Closer to reclaiming the SMA200 than MDT. Watch for GC.
  • AMGN ($358.33, RSI 62) — Amgen: strong-up, GC, +8.7% vs SMA200, +6.6% 30D. Cleanest large-cap accumulate in the scan — not extended (+10.9% vs VWAP vs +24-37% for the leaders).
  • TMO ($513.03, RSI 67) — Thermo Fisher: weak-up, DC, -2.3% vs SMA200, +10.1% 7D. Big EOW week; approaching SMA200 reclaim. Watch closely.

Extended / Leaders (RSI 69–73)

  • BIIB ($216.03, RSI 69) — Biogen: strong-up, GC, +22.6% vs SMA200, +30.3% vs VWAP. Alzheimer franchise holding. Extended vs VWAP; hold but don't add.
  • VRTX ($480.18, RSI 69, stale) — Vertex: up, DC, +8.8% vs SMA200, +10.4% vs VWAP. CF pipeline; basing. Hold.
  • MRK ($128.66, RSI 71) — Merck: strong-up, GC, near ATH (-0.1%), +22.7% vs SMA200, +30.5% vs VWAP (poc at $82). Keytruda re-rate confirmed but fully priced; wait for pullback to SMA20 ($118).
  • JNJ ($254.66, RSI 72) — J&J: strong-up, GC, near ATH (-0.2%), +18.3% vs SMA200, +24.3% vs VWAP (poc at $239). Diversified pharma post-Kenvue; don't chase at current level.
  • UNH ($427.89, RSI 73) — UnitedHealth: strong-up, GC, at ATH, +29% vs SMA200, +37.2% vs VWAP (poc at $282 — price is 52% above the weighted average). Managed-care recovery is fully priced. Hold if owned; do not initiate.
  • CVS ($104.34, RSI 72) — CVS Health: strong-up, GC, near ATH (-1.7%), +30.3% vs SMA200, +35.1% vs VWAP (poc at $76). Same exhaustion read as UNH. Hold; don't add.
  • LLY ($1,208.12, RSI 73) — Eli Lilly: strong-up, GC, near ATH (-0.6%), +24.1% vs SMA200, +33.6% vs VWAP (poc at $1029). GLP-1 oligopoly compounder. Hold position; not a new-entry at these levels.
  • MRNA ($67.27, RSI 71) — Moderna: strong-up, GC, +25.9% above SMA20, +67.6% vs SMA200, +82% vs VWAP (poc at $25 — truly parabolic). Hold if owned from lower; do not initiate.

Entry Zones

Stock Price Zone RSI 30D% Setup
AMGN $358.33 <$350 (SMA20 retest) 62.3 +6.6% Large-cap basing; GC; +8.7% vs SMA200; +10.9% vs VWAP = not extended; best entry in scan
GILD $127.88 <$126 (SMA20 support) 51.7 -3.7% Basing on SMA200; GC; +2.5% vs VWAP; cleanest oversold-adjacent setup
PFE $24.29 <$23.50 36.2 -7.3% Lone deep-oversold (RSI 36); GC; on SMA200; contrarian probe only — wait for a daily close above SMA20
MRK $128.66 <$120 (SMA20 pullback) 70.8 +7.8% Keytruda; GC; near ATH; strong thesis — add on SMA20 pullback, not at current +30.5% vs VWAP
TMO $513.03 Watch SMA200 reclaim ($524.86) 66.5 +12.6% Lab-tools; DC; +10.1% 7D, approaching SMA200; add on confirmed reclaim, not before

Action Matrix

Action Stocks Why
🔒 HOLD UNH, JNJ, MRK, LLY, CVS, AMGN, BIIB, VRTX, MRNA Trends intact; don't sell strength — but don't add at current VWAP premiums
📈 ACCUMULATE AMGN Only large-cap not extended vs VWAP; GC; clean basing setup; add on SMA20 retest
🔍 WATCH PFE, GILD, TMO, SYK, MDT, ABT, DXCM PFE lone oversold; TMO approaching SMA200 reclaim; rest are relief rallies in downtrends
⚠️ EXTENDED / DON'T CHASE UNH, CVS, JNJ, MRK, LLY, MRNA RSI 71-73 with 24-82% above VWAP; managed care / pharma re-rate is fully priced
❌ BROKEN / AVOID ISRG, ZTS, VEEV Collapse/strong-down; DC; -17 to -36% vs SMA200; structural de-rates with no reversal signal

What Changed This Week (EOW)

  • MRK +10.2% 7D — the week's standout — Merck reached near-ATH (-0.1%) with RSI 71; +30.5% vs VWAP signals the Keytruda/vaccine re-rate is now a full consensus trade.
  • JNJ +6.6% 7D, near ATH — RSI jumped to 72.4 (from ~65 prior week); the post-Kenvue large-cap pharma thesis fully confirmed.
  • LLY crossed $1,200 — +37.8% 3M, RSI 73, near ATH; GLP-1 oligopoly trade now 33.6% above VWAP (poc at $1029).
  • UNH crossed ATH — RSI 72.6, +66.1% 3M, +37.2% vs VWAP (poc at $282); managed care recovery is the year's best large-cap run.
  • PFE deepened — RSI 36.2 (was 27 prior week — wait, note the prior scan had PFE RSI 26.9; now 36.2 is actually HIGHER, meaning some recovery; but -5.2% 7D contradicts that — data discrepancy with yesterday vs today's fresh bar). Today's bar: price $24.29 (-5.2% 7D), RSI 36.2, GC, -3.8% vs SMA200. Still the lone oversold watch.
  • TMO big week — +10.1% 7D, RSI 66.5, approaching SMA200 ($524.86 vs price $513); the SMA200 reclaim is the key trigger to watch next week.
  • ZTS/ISRG no change — Both remain in structural collapse; ZTS now -53% from ATH (worst name in scan).

Key Discoveries

Discovery Implication
UNH/CVS/JNJ/MRK all near ATH with RSI 71-73 Healthcare large-cap re-rate is COMPLETE for this cycle — the entry was 2-3 months ago; now it's hold territory only
AMGN +10.9% vs VWAP vs UNH +37.2% vs VWAP AMGN is the only major name where risk/reward is still reasonable — significant divergence from managed care peers
TMO +10.1% 7D approaching SMA200 reclaim Lab-tools may be next to re-rate; the SMA200 reclaim is the tell — watch next week

Mistakes (Don't Repeat)

Mistake Lesson
Chasing UNH/CVS after managed care re-rate ran +37% vs VWAP is exhaustion territory; the right entry was when RSI was 40-50 in the collapse phase
Treating TMO/ABT 30D bounces as SMA200 reclaims TMO still -2.3% below SMA200 (DC); ABT still -15.7% below SMA200; bounces ≠ reclaims
Ignoring ZTS collapse as "it can't go lower" -53% from ATH with no reversal = falling knife; avoid until DC flips

Open Questions

  • PFE RSI 36 with GC: Is this the contrarian turn or does it flush below the SMA200 first?
  • TMO: Does it reclaim the SMA200 ($524.86) next week and flip the trend, or does the DC cap it?
  • UNH +66.1% 3M at ATH: Exhaustion top, or does the managed care re-rate have a second leg into Q3?
10 events
DateTypeEvent
Jun 25 ScanHealthcare Scan Jun 16 ScanHealthcare Scan Jun 20 ScanHealthcare Scan Jul 11 ScanHealthcare Scan Jul 7 ScanHealthcare Scan Jul 17 ScanHealthcare Scan May 29 ScanHealthcare Scan Jul 25 ScanHealthcare Scan Jul 28 ScanHealthcare Scan Jul 31 ScanHealthcare Scan

No direct external sources are attached to this read.